Webinar Date/Time: Thu, Feb 13, 2025 11:00 AM EST
Join this webinar to learn how to set up and run an Aunty experiment. Get a walkthrough of Aunty’s data analysis of Tm & Tagg and colloidal stability experiments, and get a peek at the highest resolution stability data you’ve ever seen.
Register Free: https://www.biopharminternational.com/bp_w/meet-aunty
Event Overview:
Testing stability of your proteins and formulations can feel like being buried alive when screening boat loads of candidates and conditions. Most classic tools are either inflexible, one-hit wonders that don’t give the full stability picture or seriously low-throughput, creating major bottlenecks that eat up valuable time you need for everything else you’ve got to get done, like yesterday.
Aunty is the fastest and highest throughput protein stability characterization tool on the planet. Load up to 96 of your samples into its plate and Aunty will power through piles of thermal melting and aggregation experiments at unmatched speeds - reading fluorescence, SLS and DLS of the whole plate every minute of a thermal ramp. Screen gobs of candidates and conditions with as many replicates as you want. Aunty busts out plates of results with unprecedented speed and data resolution.
Join this webinar to see how to set up and run an Aunty experiment. Get a walk-through of Aunty’s data analysis of Tm & Tagg and colloidal stability experiments and get a peek at the highest resolution stability data you’ve ever seen.
Speaker:
Andre Mueller, PhD
Marketing Manager, Biologic Solutions
Unchained Labs
Andre Mueller, PhD, is the Product Manager for Aunty and Honeybun at Unchained Labs supporting the development of new biologic and gene therapy drugs. His expertise covers fluorescence, static light scattering, and dynamic light scattering for biophysical characterization of proteins and viral vectors. His research experience spans from structural biology to plant physiology, and he worked in labs in Germany, Sweden, Denmark, and the USA. Andre earned his PhD at the Carlsberg Laboratory and had a postdoctoral appointment at Stanford University.
Register Free: https://www.biopharminternational.com/bp_w/meet-aunty
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.